Abstract
Cellular interactions among platelets, leukocytes and endothelial cells are considered as a major cause of inflammation and atherosclerosis in many diseases. Via exposed surface receptors and released soluble substances, activated platelets play a crucial role in the initiation of inflammatory processes, resulting in endothelial injury and leading to formation of atherosclerotic plaque with possible thrombotic complications. Classic anti-platelet treatments (e.g. cyclooxygenase inhibitor or ADP-receptor antagonist) have favorable effects in patients with vascular diseases, but they also have several limitations such as increased bleeding risk or non-responsiveness. Thus, the need and opportunities for developing novel therapeutic inhibitors for platelet-mediated events are obvious. Animal and (pre)clinical human studies have suggested that some recently produced specific antagonists of P-selectin from α-granules, as well as its main ligand/receptor P-selectin Glycoprotein Ligand-1, the two major platelet chemokines CXCL4 and CCL5, as well as CD40L, may be considered potential new candidates in the treatment of atherogenesis and inflammation. In this review, we summarize the pathophysiological roles of these effectors in platelet activation and acute or chronic inflammation, and discuss the latest findings on promising antagonistic agents in basic and clinical studies in the prevention of platelet-mediated cellular interactions.
Keywords: Antiplatelet therapy, atherosclerosis, CD40L, chemokine, endothelial cell, inflammation, leukocyte, microparticle, plaque formation, platelet, P-selectin, PSGL-1, vascular disorder
Current Medicinal Chemistry
Title: Potential Therapeutic Targeting of Platelet-Mediated Cellular Interactions in Atherosclerosis and Inflammation
Volume: 19 Issue: 4
Author(s): B. Nagy Jr., K. Miszti-Blasius, A. Kerenyi, K. J. Clemetson and J. Kappelmayer
Affiliation:
Keywords: Antiplatelet therapy, atherosclerosis, CD40L, chemokine, endothelial cell, inflammation, leukocyte, microparticle, plaque formation, platelet, P-selectin, PSGL-1, vascular disorder
Abstract: Cellular interactions among platelets, leukocytes and endothelial cells are considered as a major cause of inflammation and atherosclerosis in many diseases. Via exposed surface receptors and released soluble substances, activated platelets play a crucial role in the initiation of inflammatory processes, resulting in endothelial injury and leading to formation of atherosclerotic plaque with possible thrombotic complications. Classic anti-platelet treatments (e.g. cyclooxygenase inhibitor or ADP-receptor antagonist) have favorable effects in patients with vascular diseases, but they also have several limitations such as increased bleeding risk or non-responsiveness. Thus, the need and opportunities for developing novel therapeutic inhibitors for platelet-mediated events are obvious. Animal and (pre)clinical human studies have suggested that some recently produced specific antagonists of P-selectin from α-granules, as well as its main ligand/receptor P-selectin Glycoprotein Ligand-1, the two major platelet chemokines CXCL4 and CCL5, as well as CD40L, may be considered potential new candidates in the treatment of atherogenesis and inflammation. In this review, we summarize the pathophysiological roles of these effectors in platelet activation and acute or chronic inflammation, and discuss the latest findings on promising antagonistic agents in basic and clinical studies in the prevention of platelet-mediated cellular interactions.
Export Options
About this article
Cite this article as:
Nagy Jr. B., Miszti-Blasius K., Kerenyi A., J. Clemetson K. and Kappelmayer J., Potential Therapeutic Targeting of Platelet-Mediated Cellular Interactions in Atherosclerosis and Inflammation, Current Medicinal Chemistry 2012; 19 (4) . https://dx.doi.org/10.2174/092986712798918770
DOI https://dx.doi.org/10.2174/092986712798918770 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Juvenile Systemic Lupus Erythematosus
Current Pediatric Reviews Aliskiren: A Novel Renin Inhibitor for Hypertension
Current Drug Therapy NF-κB as a Therapeutic Target for Transcription Factor Decoy Strategy in Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Is the Vascular System a Main Target for Thyroid Hormones? From Molecular and Biochemical Findings to Clinical Perspectives
Current Vascular Pharmacology Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety Non-Traditional Systemic Treatments for Diabetic Retinopathy: An Evidence-Based Review
Current Medicinal Chemistry Induction of Myocardial Fibrosis and Hypertrophy by Natriuretic Peptides
Vascular Disease Prevention (Discontinued) Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Adrenomedullin in Vascular Endothelial Injury and Combination Therapy: Time for a New Paradigm
Current Vascular Pharmacology SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature
Current Clinical Pharmacology Arachidonate Cascade in the Intensive Insulin Therapy for Critically Ill Patients with Sepsis: Roles of Prostaglandins on Hyperglycemia-Impaired Immunity
Letters in Drug Design & Discovery Approaches for Imaging the Diabetic Pancreas: First Results
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Herb-Drug Interactions: An Evidence Based Approach
Current Medicinal Chemistry Chemokines and Receptors as Targets in Anti-Inflammatory Therapy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Nuclear Magnetic Resonance Spectroscopy and Genetic Disorders
Current Medicinal Chemistry Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal Current Status of Antiplatelet Therapy in Acute Coronary Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Contemporary Risk Assessment and Cardiovascular Outcomes in Peripheral Arterial Disease
Cardiovascular & Hematological Disorders-Drug Targets Metabolic Syndrome: Clinical Features Leading to Therapeutic Strategies
Vascular Disease Prevention (Discontinued)